BYSI: מחיר רכישת החברה BeyondSpring Inc

BeyondSpring Inc. (BYSI) develops cutting-edge oncology treatments, where the drug Plinabulin simultaneously suppresses tumors and minimizes therapy toxicity. The brand's high authority among physicians is driven by the effective protection of patients' immunity during chemotherapy. The operating model relies on external contractors to conduct research. A retrospective of the share price shows an Enterprise Value of 10.91, confirming the current market valuation of the business.

Enterprise Value determines the total buyout price of a business by combining market capitalization and debt, minus liquid assets. This metric reflects the actual cost for a buyer to acquire all assets. When analyzing the aggregate asset valuation of a company, it is essential to consider default risks. For BeyondSpring Inc. (BYSI), this indicator is critical due to its reliance on foreign patents, as geopolitical barriers in pharmacology could impair these assets.